Simurosertib (TAK-931) is primarily investigated for its potential in cancer treatment, particularly as a cell division cycle 7 (CDC7) kinase inhibitor. By targeting CDC7, it disrupts the DNA replication process in cancer cells, preventing their proliferation. This mechanism is especially promising in treating solid tumors and hematologic malignancies where uncontrolled cell division is a hallmark. Clinical trials are ongoing to evaluate its efficacy and safety in patients with advanced or refractory cancers. Additionally, research explores its use in combination therapies to enhance the effectiveness of existing cancer treatments. Its ability to selectively inhibit CDC7 makes it a valuable candidate for precision medicine in oncology.